作为性结肠炎的并发症,一种罕见的皮肤质性病例:病例报告和文献综述
Amin Shah1, Anubhav Sharma1, Agnimshwor Dahal2
1Kathmandu Medical College and Teaching Hospital Kathmandu Nepal.
Clinical case reports
|October 20, 2025
概括
皮肤性疹是一种性结肠炎的罕见并发症,经常出现不寻常的皮肤. 早期诊断和用皮质类固醇和免疫抑制剂治疗是管理这种疾病的关键.
科学领域:
- 皮肤病学 皮肤病学
- 胃肠病学 胃肠病学
- 内部医学 内部医学
背景情况:
- 皮肤病 (Pyoderma gangrenosum,简称PG) 是一种罕见的,具有破坏性的中性恋性皮肤病.
- 它可以表现为炎症性肠病 (IBD) 的肠外并发症,特别是性结肠炎 (UC).
- 在IBD患者的非典型皮肤需要考虑PG.
研究的目的:
- 为了突出一个患有性结肠炎的患者的皮肤质性病例.
- 为了强调诊断重要性的pathergy现象和性病变.
- 强调早期识别和治疗对改善患者结果的好处.
主要方法:
- 案例报告的呈现方式.
- 皮肤病变的临床检查.
- 对患者炎症性肠道疾病病史的审查.
- 诊断考虑的pathergy现象. 这种情况.
主要成果:
- 患者出现了不典型的皮肤.
- 观察到的是一种"pathergy"现象.
- 确立了与性结肠炎相关的皮肤质性结肠炎的诊断.
- 及时使用皮质类固醇和免疫抑制疗法治疗导致改善的结果.
结论:
- 皮肤性性肠炎是一种显著的,尽管很少见的,性结肠炎的肠外表现.
- 皮现象和特征性病变是重要的诊断指标.
- 早期诊断和积极的治疗对于IBD患者的PG有效治疗至关重要.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
891
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
891
Chronic Bowel Disorders: Introduction
744
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
744
Peptic Ulcer Disease I: Introduction
740
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
740
Gastritis III: Clinical Manifestations and Management
1.2K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.2K
Inflammatory Bowel Disease II: Crohn's Disease
947
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
947
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
534
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
534
